The short version of Visceral adiposity fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-15. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
==== Federal regulation ==== In March 2016, OSHA mandated that companies must provide certain safety measures for employees who work with or around silica, in order to prevent silicosis, lung cancer, and other silica-related diseases. As part of the updated standard, OSHA created a table of engineering and administrative control methods to reduce silica exposure when using specific tools in 18 different applications that are known to create an exposure to silica. The key provisions of the updated standard include:
Microscopically, each liver lobe is seen to be made up of hepatic lobules. The lobules are roughly hexagonal, and consist of plates of hepatocytes, and sinusoids radiating from a central vein towards an imaginary perimeter of interlobular portal triads. The central vein joins to the hepatic vein to carry blood out from the liver. A distinctive component of a lobule is the portal triad, which can be found running along each of the lobule's corners. The portal triad consists of the hepatic artery, the portal vein, and the common bile duct. The triad may be seen on a liver ultrasound, as a Mickey Mouse sign with the portal vein as the head, and the hepatic artery, and the common bile duct as the ears. Histology, the study of microscopic anatomy, shows two major types of liver cells: parenchymal cells and nonparenchymal cells. About 70–85% of the liver volume is occupied by parenchymal hepatocytes. Nonparenchymal cells constitute 40% of the total number of liver cells but only 6.5% of its volume. The liver sinusoids are lined with two types of cell, sinusoidal endothelial cells, and phagocytic Kupffer cells. Hepatic stellate cells are nonparenchymal cells found in the perisinusoidal space, between a sinusoid and a hepatocyte. Additionally, intrahepatic lymphocytes are often present in the sinusoidal lumen.
By 1945 she had succeeded in identifying the structure of vitamin B12, describing the arrangement of its atoms in three dimensions. In 1947, she was elected a Fellow of the Royal Society (FRS) In 1958, she was elected a Foreign Honorary Member of the American Academy of Arts and Sciences. Hodgkin won the 1964 Nobel Prize in Chemistry, and is the only British woman scientist to have been awarded a Nobel Prize in any of the three sciences it recognizes. In 1965 she was appointed to the Order of Merit. She was the second woman to receive the Order. In 1966, she was awarded the Iota Sigma Pi National Honorary Member for her significant contribution. In 1970, gained EMBO Membership. She became a foreign member of the USSR Academy of Sciences in the 1970s. In 1976, she was the first woman to receive the prestigious Copley Medal. Hodgkin was Chancellor of the University of Bristol from 1970 to 1988. In 1978, she was given an honorary Degree of Science from University of Bath. In 1981, she was awarded the Dalton Medal from the Manchester Literary and Philosophical Society In 1982 she received the Lomonosov Medal of the Soviet Academy of Sciences. In 1987 she accepted the Lenin Peace Prize from the government of Mikhail Gorbachev. In 1983, Hodgkin received the Austrian Decoration for Science and Art. In 1993, an asteroid (5422) discovered on 23 December 1982 by L.G. Karachkina (at the Crimean Astrophysical Observatory, M.P.C. 22509, in the USSR) was named "Hodgkin" in her honour.
These clinical results were replicated in a similar operation undertaken in 1934 by the neurosurgeon Roy Glenwood Spurling and reported on by the neuropsychiatrist Spafford Ackerly. By the mid-1930s, interest in the function of the frontal lobes reached a high-water mark. This was reflected in the 1935 neurological congress in London, which hosted as part of its deliberations, "a remarkable symposium ... on the functions of the frontal lobes". The panel was chaired by Henri Claude, a French neuropsychiatrist, who commenced the session by reviewing the state of research on the frontal lobes, and concluded that "altering the frontal lobes profoundly modifies the personality of subjects". This parallel symposium contained numerous papers by neurologists, neurosurgeons and psychologists; amongst these was one by Brickner, which impressed Moniz greatly, that again detailed the case of "Patient A". Fulton and Jacobsen's paper, presented in another session of the conference on experimental physiology, was notable in linking animal and human studies on the function of the frontal lobes. Thus, at the time of the 1935 Congress, Moniz had available to him an increasing body of research on the role of the frontal lobes that extended well beyond the observations of Fulton and Jacobsen. Nor was Moniz the only medical practitioner in the 1930s to have contemplated procedures directly targeting the frontal lobes.
Sources: en.wikipedia.org
=== Streptomyces === Daptomycin is another naturally occurring lipidated peptide, produced by the Gram positive bacterium Streptomyces roseoporous. The structure of Daptomycin consists of a decanoyl lipid chain attached to a partially cyclised peptide head group. It has very potent antimicrobial properties and is used as an antibiotic to treat life-threatening conditions caused by Gram positive bacteria including MRSA (methicillin-resistant Staphylococcus aureus) and vancomycin resistant Enterococci. As with the Bacillus subtilis lipidated peptides, the permeation of the cell membrane is what gives it its properties, and the mechanism of action with daptomycin is thought to involve the insertion of the decanoyl chain into the bacterial membrane to cause disruption. This then causes a serious depolarization resulting in the inhibition of various synthesis processes including those of DNA, protein and RNA, leading to apoptosis.
leptonema Also leptotene stage. In meiosis, the first of five substages of prophase I, following interphase and preceding zygonema. During leptonema, the replicated chromosomes condense from diffuse chromatin into long, thin strands that are much more visible within the nucleus.
Tho told Kissinger that the Khmer Rouge's leader, Pol Pot, was a Vietnamphobe and that North Vietnam had very limited influence over him. At the same time, Kissinger reported to Nixon that "only a miracle" could save South Vietnam now, as Thiệu showed no signs of making the necessary reforms to allow the ARVN to fight. His assessment of Cambodia was even bleaker, as the Lon Nol regime had lost control of much of the countryside by the spring of 1973, and only American air strikes prevented the Khmer Rouge from taking Phnom Penh. Between March–May 1973, American bombers dropped 95,000 tons of bombs on Cambodia, while American fighters dropped another 15,000 tons of bombs. On 4 June 1973, the Senate passed a bill that already cleared the House of Representatives to block funding for any American military operations in Indochina, and Kissinger spent much of the summer of 1973 lobbying Congress to extend the deadline to 15 August in order to keep bombing Cambodia. The Lon Nol regime was saved in 1973 due to heavy American bombing, but the cutoff in funding ended the possibility of an American return to Southeast Asia. The PAVN had taken heavy losses in the Easter Offensive, but the North Vietnamese were rebuilding their strength for a new offensive. By the spring of 1973, Nixon was caught up in the Watergate scandal and was losing interest in foreign affairs. Kissinger was angry that the Secretary of State, William Rogers, had not resigned so he take could over the State Department, shouting: "And now's he's hanging on just as I said he would. Piece by piece. Bit by bit.
Some instruments measure the average amount of hemoglobin in each reticulocyte; a parameter that has been studied as an indicator of iron deficiency in people who have conditions that interfere with standard tests. The immature reticulocyte fraction (IRF) is another measurement produced by some analyzers which quantifies the maturity of reticulocytes: cells that are less mature contain more RNA and thus produce a stronger fluorescent signal. This information can be useful in diagnosing anemias and evaluating red blood cell production following anemia treatment or bone marrow transplantation.
Because the plant has not been well-studied in high-quality clinical research, little is known about its toxicology, adverse effects, or safety over long-term consumption. Its chief active psychoactive constituent is a structurally unique diterpenoid called salvinorin A, a potent κ-opioid agonist. Although not thoroughly assessed, preliminary research indicates S. divinorum may have low toxicity (high LD50). Its effects are rapid but short-lived.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.